🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer

Recruitingn/aAges 45 Years - 80 YearsAllShanghai Chest Hospital of Shanghai Jiao Tong Uni…
NCT07070011 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to investigate the clinical value of small extracellular vesicle (sEV) miRNAs as predictive biomarkers for immunochemotherapy efficacy in extensive-stage small cell lung cancer (ES-SCLC). ES-SCLC represents a highly aggressive neuroendocrine malignancy, where the current standard first-line treatment combining immune checkpoint inhibitors with chemotherapy lacks predictive biomarkers for individualized therapeutic strategies. A prospective observational cohort will be established at Shanghai Chest Hospital, enrolling treatment-naïve ES-SCLC patients. Distinct miRNA signatures differentiating responders from non-responders will be identified through pretreatment serum sEV miRNA sequencing and differential expression analysis. These findings may provide novel liquid biopsy biomarkers to guide personalized treatment strategies and optimize clinical decision-making in ES-SCL

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Requirements for patients enrolled in the project: 1. The pathological diagnosis of the patient is ESSCLC; 2. ECOG score 0 or 1； 3. The patient is receiving immunotherapy combined with chemotherapy for the first time and has no history of chemotherapy treatment; 4. Patients with complete clinical sample information who meet the inclusion requirements Exclusion Criteria: 1. Patients whose pathological diagnosis does not meet the requirements; 2. Patients whose ECOG staging does not meet the requirements; 3. Patients with a history of chemotherapy, immunotherapy, or immunotherapy combined with chemotherapy; 4. Patients with incomplete clinical sample information and follow-up information;
💊

What it tests

  • EC/EP + ICIs
📍

Where

1 site
Shanghai Chest Hospital
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy